For example, semi-selective KDM4 inhibitors that abrogate KDM4B activity have been shown to be efficacious in inhibiting AR-signalling and growth in prostate cancer cells and to be effective in inhibiting the growth of MYC-driven neuroblastomas and breast cancer stem-like cells [52,53,54,55]. Here, MYC is linked to prostate cancer.